Follow-up of prostate cancer;Suivi du cancer de la prostate

Progres en Urologie

Volumn 15, Issue 4, 2005, Pages 586-592

  Richaud, Pierre ^a,b   Moreau, Jean Luc ^a   Beuzeboc, Philippe ^a   Rébillard, Xavier ^a   Villers, Arnaud ^a   Peyromaure, Michaël ^a   Cornud, François ^a   Soulié, Michel ^a   Davin, Jean Louis ^a  

^a Comité Prostate du CCAFU ^*  (France)

^b INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLOW UP; HEALTH SURVEY; HUMAN; MALE; METASTASIS; PATHOLOGY; PRACTICE GUIDELINE; PROSTATE TUMOR; REVIEW; TUMOR RECURRENCE;

FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POPULATION SURVEILLANCE; PROSTATIC NEOPLASMS;

EID: 27644453056     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. ADOLFSSON J., STEINECK G., HEDLUND P.O. : Deferred treatment of clinically localized prostate cancer. Urology, 1997 ; 50 : 722-726.
2. AMLING C.L., BERGSTRAHL E.J., BLUTE M.L., SLEZAK J.M., ZINCKE H. : Defining prostate specific antigen progression after radical prostatectomy : what is the most appropriate cut point ? J. Urol., 2001 ; 165 : 1146-1151.
3. ANONYMOUS : Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Working Party Investigators Group. British J. urol., 1997 ; 79 : 235-246.
4. ANAGNOSTOU T., DOUMAS K., REMZI M.,DJAVAN B. : Postradical prostatectomy TRUS-guided anastomotic biopsy. Where do we stand today ? Prostate Cancer and prostatic Diseases, 2004 ; 7 : 302-310.
5. AUS G., HUGOSSON J., NORLÉN L. : Long term survival and mortality in prostate cancer treated with noncurative intent. J. Urol., 1995 ; 154 : 460-465.
6. AUS G., ABBOU C.C., BOLLA M., HEIDENREICH A., VAN POPPEL H., SCHMID H-P., WOLFF J.M., ZATTONI F. : Guideline on prostate cancer. EAU update march 2005. European Association of Urology.
7. ASTRO : Consensus statement : guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int. J. Radiat. Oncol. Biol. Phys., 1997 ; 37 : 1035-1041.
8. BRASSO K., FRIIS S., JUEL K. et AL. : Mortality of patients with clinically localised prostate cancer treated with observation for 10 years or longer: a population based study. J. Urol. ; 1999 ; 161 : 524-528.
9. BUBLEY G.J., CARDUCCI M., DAHUT W., et AL. : Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer : recommendations from the Prostate Specific Antigen Working Group. J. Clin. Oncol. 1999 ; 17 : 3461-3467.
10. BUYYOUNOUSKI M.K., HANLON A.L., HORWITZ E.M., UZZO R.G. and POLLACK A. : Biochemical failure and the temporal kinetics of prostate specific antigen after radiation therapy with androgen deprivation. Int. J. Radiation Oncology Biol. Phys., 2005 ; 61 : 1291-1298.
11. CHODAK G.W., THISTED R.A., GERBER G.S., JOHANSSON J.E., ADOLFSOSON J., JONES G.W. et AL. : Results of conservative management of clinically localised prostate cancer. N. Eng. J. Med., 1994 ; 330 : 242-248.
12. CHODAK G.W., IVERSEN P., MC LEOD D.G., ET AL : Program and abstracts of the American Urological Association Annual Meeting ; May 21-26, 2005 ; San Antonio, Texas. Abstract 1013.
13. CHOO R., KLOTZ L., DANJOUX C., MORTON G.C., DEBOER G., SZUMACHER E. ET AL : Feasibility study : watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progresion. J. Urol., 2002 ; 167 : 1664-1669.
14. CRITZ F.A., LEVINSON A.K., WILLIAMS W.H., HOLLADAY D.A., HOLLADAY C.T. : The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urol., 1997 ; 49 : 322-326.
15. CROOK J.M., BAHADUR Y.A., BOCIEK R.G. et AL. : Radiotherapy for localised prostate carcinoma. The correlation of pre-treatment prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer, 1997 ; 79 : 328-336.
16. CROOK J.M., CHOAN E., PERRY G.A., ROBERTSON S., ESCHEW B.A.: Serum prostate-specific antigen profile following radiotherapy for prostate cancer : implications for patterns of failure and definition of cure. Urology, 1998 ; 51 : 566-572.
17. D'AMICO A.V., WHITTINGTON R., MALKOWICZ S.B., SCHULTZ D., BLANK K., BRODERICK G.A., TOMASZEWSKI J.E., RENSHAW A.A., KAPLAN I., BEARD C.J., ALAN WEIN A. : Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA, 1998 ; 280 : 969-974.
18. D'AMICO A.V., MOUL J., CARROLL P.R., SUN L., LUBECK D., CHEN M.H. : Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radiac prostatectomy or radiation therapy. J. Urol., 2004 ; 172 : S42-S46.
19. DIAMOND T.H., HIGANO C.S., SMITH M.R., GUISE T.A., SINGER F.R.: Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy : recommendations for diagnosis and therapies. Cancer, 2004 ; 100 : 892-899.
20. FERGUSON J.K., OSESTERLING J.R. : Patient evaluation if prostate cancer antigen becames elevated following radical prostatectomy or radiation therapy. Urol. Clin. North Am., 1994 ; 21 : 677-685.
21. HAESE A., HULAND E., GRAEFEN M., HAMMERER P., NOLDUS J., HULAND H. : Ultrasensitive detection of prostate-specific antigen in the followup of 422 patients after radical prostatectomy. J. Urol., 1999 ; 161 : 1206-1211.
22. HANLON A., DIRATZOUIAN H., HANKS G.E. : Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death fram prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2002 ; 53 : 297-303.
23. HANCOCK S.L., COX R.S., BAGSHAW M.A. : Prostate-specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University. J. Urol., 1995 ; 154 : 1412-1417.
24. HELLMAN L., BRADLOW H.L., FREED S., LEVIN F.J., ROSENFELD R.S., WHITMORE W.F., ZUMOFF B. : The effect of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins. J. Clin. Endocrinol. Metab., 1977 ; 45 : 1224-1229.
25. JOHANSSON J.E., ADAMI H.O., ANDERSON S.O. et AL. : High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA, 1992; 267 : 2191-2196.
26. KLOTZ L.H., CHOO R., MORTON G., DANJOUX C. : Expectant management with selective delayed intervention for favorable-risk prostate cancer. Can. J. Uro., 2002 ; 9 : 2-7.
27. LATTOUF J.B., SAAD F. : Digital rectal exam following prostatectomy : is it still necessary with the use of PSA ? Eur. Urol., 2003 ; 43 : 333-336.
28. MERRICK G.S., WALLNER K.E., BUTLER W.M. : Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J. Urol., 2003. 169 : 1643-1652.
29. MOUL J.W., ANDERSON J., PENSON D.F., KLOTZ L.H., SOLOWAY M.S., SCHULMAN C.C. : Early prostate cancer : prevention, treatment modalities, and quality of life issues. Eur. Urol., 2003 ; 44 : 283-293.
30. NEWLING D. : Advanced prostate cancer : immediate versus deferred hormone therapy ? Eur. Urol., 2001 ; 39 : 15-21.
31. OBEK C., NEULANDER E., SADEK S., SOLOWAY M.S. : Is there a role for digital rectal examination in the followup of patients after radical prostatectomy ? J. Urol., 1999 ; 162 : 762-764.
32. OEFFELEIN M.G., RESNICK M.I. : Effective testosterone suppression for patients with prostate cancer: is there a best castration ? Urology, 2003 ; 62: 207-213.
33. PARTIN A.W., PEARSON J.D., LANDIS P.K., CARTER H.B., POUND C.R., CLEMENS J.Q., EPSTEIN J.I. and WALSH P.C. : Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant to distinguish local recurrence from distant metastases. Urology, 1993 ; 43 : 649-659.
34. PATEL A., DOREY F., FRANKLIN J., DEKERNION J.B. : Recurrence patterns radical retropubic prostatectomy : clinical usefulness of prostate-specific antigen doubling times and log slope prostate specific antigen. J. Urol., 1997 ; 158 : 1441-1445.
35. PEARSON J.D. AND CARTER H.B. : Natural History of changes in prostate-specific antigen in early stage prostate cancer. J. Urol., 1994 ; 152 : 1743-1748.
36. POISSONNIER L., GELET A., CHAPELON J.Y., BOUVIER R., ROUVIERE O., PANGAUD C., LYONNET D., DUBERNARD J.M. : Résultats du traitement par ultrasons focalisés transrectaux du cancer localisé de la prostate (120 patients avec PSA ≤ à 10 ng/ml). Prog. Urol., 2003 ; 13 : 60-72.
37. POLLACK A., HANLON A., PISANSKI T.M., SANDLER H.M., KUBAN D.A., CATTON, MICHALSKI J.M., ZELEFSKI M.J., KUPELIAN P.A., KESTIN L.L., VALICENTI R.K., DEWEESE T.L. : Which definition of biochemical failure after post-operative radiotherapy predicts best for clinical failure ? A milti-institutional analysis. Program and abstracts of the American Urological Association Annual Meeting ; May 21-26, 2005 ; San Antonio, Texas. Abstract 1136.
38. POUND C.R., PARTIN A.W., EPSTEIN J.I., WALSH P.C. : Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol. Clin. North Am., 1997 ; 24: 395-406.
39. REBILLARD X., SOULIE M., DAVIN J.L. et CCAFU : Traitement par HIFU du cancer de la prostate : revue de la littérature et indications de traitement. Prog. Urol., 2003 ; 13 : 1428-1457.
40. ROSSER C.J., KUBAN D.A., LEVY L.B., CHICHAKLI R., POLLACK A., LEE A.K., PISTERS L.L. : Prostate-specific antigen bounce phenomenon after external beam radiation for clinically localizes prostate cancer. J. Urol., 2002 ; 168 : 2001-2005.
41. SCHACHTER L.R., TEPER E., BROOKLYN N.Y., RABOY A., ALBERT P. : The relationship between PSA nadir and outcome in patients with clinically localized cancer treated with combination radiotherapy. Program and abstracts of the American Urological Association Annual Meeting ; May 21-26, 2005 ; San Antonio, Texas. Abstract 1026.
42. SCHER H.I., EISENBERGER M., D'AMICO A.V., HALABI S., SMALL F.J., MORRIS M., et AL. : Eligilibity and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen : recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol., 2004 ; 22 : 537-556.
43. SCHILD S.E., WONG W.W., NOVICKI D.E., FERRIGNI R.G. and SWANSON S.K. : Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay. Urology, 1996 ; 47 : 878-881.
44. STAMEY T.A., MCNEAL J.E., YEMOTO C.M., SIGAL B.M., JOHNSTONE I.M. : Biological determinants of cancer progression in men with prostate cancer. JAMA, 1999 ; 281 : 1395-1400.
45. STEINBERG G.D., BALES G.T., BRENDLER C.B. : An analysis of watchful waiting for clinically localized prostate cancer. J. Urol., 1998 ; 159: 1431-1436.
46. STONE N.N., STOCK R.G. : Practical considerations in permanent brachytherapy for localized adenocarcinoma of the prostate. Urol. Clin. N. Am., 2003 ; 30 : 351-362.
47. ZAGARS G.K. AND POLLACK A. : Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother. Oncol., 1997 ; 44 : 213-221.